黄金城集团

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial

Trials. 2021-01; 
W Dioh, M Chabane, C Tourette, A Azbekyan, C Morelot-Panzini, L A Hajjar, M Lins, G B Nair, T Whitehouse, J Mariani, M Latil, S Camelo, R Lafont, P J Dilda, S Veillet, S Agus
Products/Services Used Details Operation
Recombinant Antibody Expression … (SureBlue Reserve TMB 1-Component Microwell Peroxidase Substrate, Seracare Life Sciences INC; Cat No KPL 5120-0083) to each well … and 1µg) of purified recombinant SARS-CoV-2 S1 (GenScript; Cat No Z03501) were probed using a Western blot (Figure 1E) … Get A Quote

摘要

objective: As of December, 1, 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, resulted in more than 1 472 917 deaths worldwide and death toll is still increasing exponentially. Many COVID-19 infected people are asymptomatic or experience moderate symptoms and recover without medical intervention. However, older people and those with comorbid hypertension, diabetes, obesity, or heart disease are at higher risk of mortality. Because current therapeutic options for COVID-19 patients are limited specifically for this elderly population at risk, Biophytis is developing BIO101 (20-hydroxyecdysone, a Mas receptor activator) as a new treatment option for managing patients with SARS-CoV-2 infection at th... More

关键词

20-hydroxyecdysone, Acute respiratory Distress Syndrome, BIO101, COVID-19, Inflammation, Mas receptor, Renin Angiotensin System, SARS-CoV2, angiotensin converting enzyme-2, randomised controlled trial